Xylazine (Tranq) and Residential Treatment: Wound Care, Withdrawal Planning, Naloxone, and What to Tell Admissions

Xylazine rarely comes up by name on an admissions call. People describe “fentanyl that hits different,” a sedation that lasts longer than the high, or a sore on the shin that will not close. Families describe someone who nods off for hours and is hard to wake. Those details matter, because xylazine changes how overdose is handled, how withdrawal is planned, and whether a residential program is set up to care for the wounds it causes. This post explains what xylazine is, what it means for admission to residential treatment, and exactly what to tell the admissions team before you arrive.

What Xylazine Is, in One Paragraph

Xylazine, a veterinary sedative sold on the street as “tranq,” is not an opioid and is not reversed by naloxone. It is not approved for use in people, yet the DEA’s laboratory system reported that about 23% of the fentanyl powder and 7% of the fentanyl pills it seized in 2022 contained xylazine, according to the Centers for Disease Control and Prevention (CDC). Because xylazine almost always arrives mixed with fentanyl, the CDC still advises giving naloxone in any suspected overdose, calling 911, and giving rescue breaths, since xylazine’s sedation can continue after naloxone has worked on the opioid.

The National Institute on Drug Abuse (NIDA) notes that many people take xylazine without knowing it is in their supply. NIDA also reports that, across 20 states and the District of Columbia, the share of fentanyl-related overdose deaths with xylazine detected rose from 2.9% in January 2019 to 10.9% in June 2022. Rates vary by region, and the supply changes quickly, so a person in Northern California may have been exposed without ever seeking it out.

Why Xylazine Changes the Admission Plan

From the admissions side, xylazine exposure is less about a new diagnosis and more about four practical problems that have to be planned for before day one:

• Overdose that naloxone only partly reverses: naloxone reverses the fentanyl, but xylazine can keep breathing, heart rate, and blood pressure dangerously low, so staff and family need to know rescue breathing and 911 still come next.
• Wounds that appear away from injection sites: NIDA reports that xylazine-related sores often show up elsewhere on the body, and some clinicians report them in people who smoke or snort rather than inject.
• Withdrawal that may be harder than fentanyl alone: early research cited by NIDA suggests withdrawal symptoms may be more intense with xylazine plus fentanyl, and no medical association has yet published a xylazine-specific withdrawal guideline.
• A drug screen that will not show it: standard urine drug panels do not test for xylazine, so the clinical team often learns about exposure only from what the person or family reports.

That last point is the inconvenient operational truth. If nobody mentions xylazine or a wound during the pre-admission screening, the team may plan an ordinary opioid admission and only discover the wound during the physical exam on arrival. Some wounds can be managed in a residential setting with daily dressing changes and a medical provider’s oversight. Others need hospital or wound-clinic care first. The admissions team can only make that call in advance if they are told.

Wound Care: What Residential Programs Can and Cannot Do

According to NIDA, xylazine-related wounds range from skin infections and abscesses to open, weeping ulcers, and untreated wounds can progress to dead tissue and, in rare severe cases, amputation. NIDA notes that medical associations have not issued formal treatment guidelines, but early evidence favors keeping wounds clean and open rather than closed with stitches or grafts. Wounds can heal while a person is still using, though early data suggest healing is slower with continued xylazine exposure.

In practice, this is what to expect from a residential program that accepts someone with a xylazine-related wound:

• A physical exam on arrival that documents each wound, its size, and any signs of infection.
• A dressing plan, with who changes dressings and how often written down.
• A pain plan, because these wounds hurt, and untreated pain is a common reason people leave early.
• A clear threshold for sending the person out: fever, spreading redness, a foul smell, or a wound that is getting deeper means same-day medical evaluation, not waiting for the next scheduled visit.

If a program cannot describe that plan, ask whether medical clearance from a primary care provider, urgent care, or wound clinic is needed first. Asking that question on the phone is far better than discovering the gap at intake.

Withdrawal Planning When Xylazine Is Involved

Most people exposed to xylazine are also dependent on fentanyl, so withdrawal planning starts with opioid withdrawal management and a discussion of medications for opioid use disorder, which the Substance Abuse and Mental Health Services Administration (SAMHSA) identifies as an evidence-based part of treatment. Xylazine adds uncertainty: symptoms such as anxiety, restlessness, and irritability may be stronger or last longer, and there is currently no medication approved specifically for xylazine withdrawal, so clinicians treat the symptoms they see.

Safety note: NIDA reports that most overdose deaths involving both xylazine and fentanyl also involved other substances, including benzodiazepines and alcohol. Withdrawal from alcohol or benzodiazepines can cause seizures and can be life-threatening. If either is part of the picture, withdrawal must happen under medical supervision, and nobody should stop alcohol or benzodiazepines abruptly on their own while waiting for a bed.

This is one reason a residential treatment admission for someone with xylazine exposure usually begins with a medically monitored stabilization period rather than going straight into a full group schedule.

What to Tell Admissions: A Checklist You Can Use Today

Before the screening call, write down the answers to these questions. If you are a family member, ask your loved one for permission to share them, or have them on the call with you.

1. What is being used, and how? List every substance, including alcohol, benzodiazepines, gabapentin, and stimulants, and whether each is injected, smoked, snorted, or swallowed.
2. When was the last use of each? Give a date and approximate time. This sets the withdrawal timeline.
3. Has anyone said “tranq” or noticed unusually long sedation? Mention it even if you are not sure.
4. Are there any wounds? Note how many, where on the body, roughly how large, and whether any are red, hot, draining, or smell bad. A photo taken today can help the medical team decide whether clearance is needed first.
5. Any recent overdoses? Say whether naloxone was used and whether it fully worked.
6. Current prescriptions and pharmacy. Include any buprenorphine or methadone dose.

Then ask the admissions team two direct questions: “Can your medical staff manage open wounds on site, and how often are dressings changed?” and “Do you need medical clearance before admission for someone with these wounds?” You can reach our admissions team at (877) 328-1968, and it helps to verify insurance in the same call so the clinical and financial questions are settled together.

While You Wait for a Bed

The days between the first call and admission carry real risk. Keep naloxone in the home and make sure more than one person knows where it is. If someone is unresponsive or breathing slowly, give naloxone, call 911, and give rescue breaths if you are able, then stay with them; the CDC notes that xylazine’s effects can continue after naloxone. Xylazine test strips are commercially available and offered by some harm reduction programs, according to NIDA. Keep any wound clean and covered, and get it seen the same day if it shows signs of infection.

A Note From Clinical Practice

This guidance reflects the admissions and case management work of Jonathan Beazley, CADC-CAS, M-RAS, CCMI-i. The pattern that most often delays care is not the xylazine itself but the missing detail: a wound nobody mentioned, or a benzodiazepine nobody listed. Admissions teams are not looking for reasons to turn people away. They are trying to make sure the first 72 hours are medically safe. The more specific the information on the first call, the faster that plan comes together. If you are unsure whether a program is the right fit, call (877) 328-1968 and ask the questions above.

This article is for educational purposes only and is not medical advice. It does not replace an evaluation by a licensed medical provider. If someone is unresponsive, not breathing, or breathing very slowly, call 911 immediately. If you or someone you know is in emotional crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline.